Modular Nanoparticulate Prodrug Design Enables Efficient Treatment of Solid Tumors Using Bioorthogonal Activation

Area of Science:

• Medicinal Chemistry
• Nanotechnology
• Cancer Therapeutics

Background:

• Prodrug strategies aim for localized drug delivery to minimize systemic toxicity and improve pharmacokinetics.
• Current prodrug activation methods face limitations in achieving tunable multifunctionality due to activation chemistry constraints.

Purpose of the Study:

• To design and apply a modular small-molecule caging strategy for controlled prodrug activation.
• To leverage bioorthogonal cleavage, self-immolative linkers, and in vivo catalysis for drug release.
• To enhance prodrug efficacy and selectivity in cancer treatment.

Main Methods:

• Development of a modular small-molecule caging strategy incorporating a bioorthogonal cleavage site, self-immolative linker, and aliphatic anchor.
• Utilizing nanoencapsulated palladium (Pd-NP) for in vivo catalysis of alloxylcarbamate cleavage.
• Formulating a prodrug of monomethyl auristatin E (MMAE) for targeted cancer therapy.
• Employing computational pharmacokinetic modeling to assess drug activation and tumor targeting.

Main Results:

• Achieved >90% nanoencapsulation efficiency with the aliphatic anchor.
• Demonstrated >10^4-fold increase in cytotoxicity upon prodrug activation.
• Showcased selective activation of MMAE prodrug by Pd-NP, leading to microtubule targeting and cancer cell death.
• Computational modeling indicated selective tumor activation sensitive to enhanced permeability and retention (EPR) effects.

Conclusions:

• The developed nanoencapsulated prodrug strategy enables tunable, localized drug activation.
• This approach significantly enhances cancer cell cytotoxicity while minimizing systemic exposure.
• Combination therapy with nanoencapsulated MMAE prodrug, Pd-NP, and radiation safely inhibits tumor growth, representing a significant advance in prodrug design.